PPARγ agonists, modulation of ion transporters, and fluid retention

Journal of the American Society of Nephrology

Volumn 20, Issue 12, 2009, Pages 2481-2483

  Nofziger, Charity ^a   Blazer Yost, Bonnie L ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; EPITHELIAL SODIUM CHANNEL; FARGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

DRUG EFFECT; EDITORIAL; FLUID RETENTION; HUMAN; HYPERALDOSTERONISM; IN VIVO STUDY; ION TRANSPORT; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; ELECTROLYTE BALANCE; KIDNEY; METABOLISM; MOUSE; MOUSE MUTANT;

ANIMALS; EPITHELIAL SODIUM CHANNEL; HUMANS; ION TRANSPORT; KIDNEY; MICE; MICE, KNOCKOUT; PPAR GAMMA; THIAZOLIDINEDIONES; WATER-ELECTROLYTE BALANCE;

EID: 72049121913     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009060673     Document Type: Editorial

References (15)

1. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948, 2003 (Pubitemid 37517824)
2. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 356: 2457-2471, 2007 (Pubitemid 46919772)
3. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyl L, Laaksa M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Shrha J, Smith U, Taton J, PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366: 1279-1289, 2005 (Pubitemid 41416583)
4. Wayman N, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C: Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J 16: 1027-1040, 2002 (Pubitemid 34753509)
5. Yang T, Soodvalia S: Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 943614, 2008
6. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102: 9406-9411, 2005 (Pubitemid 40923576)
7. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Med 11: 861-866, 2005 (Pubitemid 41161118)
8. + channel. Pflugers Arch 451: 445-453, 2005
9. Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, Bisi J, Ashton TT, Maurio FP, Kalsi K, West TA, Baines D, Blazer-Yost BL: PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Renal Physiol 297: F55-F62, 2009
10. Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK: GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 312: 718-725, 2005 (Pubitemid 40189571)
11. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J: Thiazolidinedione-induced fluid retention is independent of collecting duct αENaC activity. J Am Soc Nephrol 20: 721-729, 2009
12. Qayyum R, Adomaityte J: A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 8: 19-28, 2006
13. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883, 1999 (Pubitemid 30017170)
14. Krämer BK, Bergler T, Stoelcker B, Waldegger S: Mechanisms of disease: The kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. Nat Clin Pract Nephrol 4: 38-46, 2008 (Pubitemid 350308225)
15. - secretion. Am J Physiol Gastrointest Liver Physiol 297: G82-G89, 2009